Aktis Oncology, Inc. (NASDAQ: AKTS) is a Healthcare company (Biotechnology) with a market capitalization of $877M. The Maz Rating grades it against the other companies in its sector.
Aktis Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.31, Aktis Oncology, Inc. trades at 70.4x sales and 2.0x book value. Over the last twelve months it generated about $12M of revenue and a net loss of $86M. It runs a gross margin of 80.0%, an operating margin of -837.5% and a net margin of -706.8%. It shows return on equity of -26.9%, return on invested capital of -20.8% and a free cash flow yield of -10.8%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 14.22. Over the past 52 weeks the share price ranged from $13.96 to $34.19, with a beta of 0.45.
Aktis Oncology, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Aktis Oncology, Inc. (AKTS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 44.6% / 30% · Interest income / Revenue 123.5% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 44.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 123.5% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 44.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 123.5% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.15% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.9% / 33.33% · Receivables / Avg Assets (4Q) 0.23% / 33.33% · Interest income / Revenue 123.5% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 92.6% / 33.33% · (Cash+Recv) / Total Assets 92.6% / 33.33% · Interest income / Revenue 123.5% / 5% | Fail |
No. As of September 2026, Aktis Oncology, Inc. (AKTS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Aktis Oncology, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 123.5% of each dividend: Aktis Oncology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.